Author: PharmaSignal News Desk

Medicare Drug Prices for 15 drugs unveiled, saving $8.5 billion, a 36% reduction.

Kelun Merck ADC shows promise in lung cancer treatment, succeeding in a late-stage trial with potential for first-line approval.

Otsuka FDA approval marks a milestone with Voyxact for IgA nephropathy, a chronic kidney disease.

Novartis FDA Approval Itvisma expands treatment for spinal muscular atrophy to older patients, priced at $2.59 million.

Bayer Asundexian trial results indicate potential for a new cardiovascular drug class, raising hopes after previous clinical setbacks.

Novo Nordisk’s GLP-1 drug semaglutide fails to slow cognitive decline in Alzheimer’s trials.

Novo Nordisk GLP-1 trials did not meet primary endpoints in Alzheimer’s studies, impacting potential neurodegeneration treatment.

J&J Alzheimer’s trial failure with posdinemab dims hopes for new treatments.

Novo Nordisk’s semaglutide failed in two Alzheimer’s trials, impacting stock by 10%.

Novo Nordisk Alzheimer’s trial with semaglutide fails to slow disease progression in over 3,800 patients.